Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
Journal Article
|Research
2023-06-06 • Lancet Microbe
2023-06-06 • Lancet Microbe
BACKGROUND
Experimental data show that drug-resistance-conferring mutations are often associated with a decrease in the replicative fitness of bacteria in vitro, and that this fitnes...
Experimental data show that drug-resistance-conferring mutations are often associated with a decrease in the replicative fitness of bacteria in vitro, and that this fitnes...
Journal Article
|Research
2021-08-30 • Antimicrobial Agents and Chemotherapy
2021-08-30 • Antimicrobial Agents and Chemotherapy
Rifampicin mono-resistant TB (RMR-TB, rifampicin resistance and isoniazid susceptibility) constitutes 38% of all rifampicin-resistant TB (RR-TB) in South Africa and is increasing. We aim...
Journal Article
|Research
2021-11-01 • Lancet Microbe
2021-11-01 • Lancet Microbe
BACKGROUND
South Africa has a high burden of rifampicin-resistant tuberculosis (including multidrug-resistant [MDR] tuberculosis), with increasing rifampicin-monoresistant (RMR) tube...
South Africa has a high burden of rifampicin-resistant tuberculosis (including multidrug-resistant [MDR] tuberculosis), with increasing rifampicin-monoresistant (RMR) tube...
Journal Article
|Research
2016-10-31 • Nature Genetics
2016-10-31 • Nature Genetics
Generalist and specialist species differ in the breadth of their ecological niches. Little is known about the niche width of obligate human pathogens. Here we analyzed a global collectio...
Journal Article
|Research
2021-10-18 • Antimicrobial Agents and Chemotherapy
2021-10-18 • Antimicrobial Agents and Chemotherapy
Rifampin monoresistance (RMR; rifampin resistance and isoniazid susceptibility) accounts for 38% of all rifampin-resistant tuberculosis (RR-TB) in South Africa and is increasing. We aime...
Journal Article
|Research
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...